Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Biocon & Equillium Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand

Posted On: 2019-12-12 22:30:43


Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company and Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that they have expanded their collaboration and license agreement for itolizumab to grant Equillium exclusive rights for developing and commercializing itolizumab in Australia and New Zealand.

Equillium had originally secured exclusive rights to develop and commercialize Biocon's novel biologic, itolizumab, for the U.S. and Canada markets, in May 2017.

"Biocon is pleased with the development progress of itolizumab achieved by Equillium so far and has agreed to include Australia and New Zealand within the scope of the licensing agreement. As an innovation-led organization we are committed to bring novel therapeutics to the market to address unmet patient needs across the world. We look forward to our continued partnership with Equillium as they develop this molecule further for the treatment of severe autoimmune and inflammatory disorders," said Siddharth Mittal, CEO and Joint Managing Director, Biocon.

"We are pleased to deepen our relationship with Biocon by expanding our licensing agreement for itolizumab. Securing these rights helps strengthen and build upon our existing presence in Australia and New Zealand where we are collaborating with distinguished asthma centers and specialists to conduct the EQUIP clinical trial in uncontrolled asthma patients," said Bruce Steel, President and Chief Business Officer of Equillium.

Itolizumab is a novel first-in-class humanized anti-CD6 monoclonal antibody, which Biocon developed and launched in India under the brand name ALZUMAb™ to treat moderate to severe plaque psoriasis in 2013. In 2017, Biocon partnered with Equillium for this promising asset to develop it for a wide range of autoimmune disorders.

In addition to the EQUIP trial in uncontrolled asthma, Equillium is conducting Phase 1b proof-of-concept clinical trials of itolizumab for the treatment of acute graft-versus-host disease (aGVHD) and lupus nephritis. The U.S. Food and Drug Administration (FDA) granted itolizumab Fast Track designation for the treatment of aGVHD and lupus nephritis, as well as Orphan Drug designations for both the prevention and treatment of aGVHD.

Shares of BIOCON LTD. was last trading in BSE at Rs.293 as compared to the previous close of Rs. 290.4. The total number of shares traded during the day was 330364 in over 2829 trades.

The stock hit an intraday high of Rs. 294.2 and intraday low of 287.2. The net turnover during the day was Rs. 95834357.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Paushak Limited receives approval for expanding production capacity of Phosgene to 14,400 MTPA

Thomas Cook (India) Limited announces results for Q1 FY21

Info Edge India Ltd fixes floor price of QIP as Rs. 3177.18

LIC ups stake in YES Bank to 4.989% through market purchase

Persistent Receives 2020 Workato Partner Award for Innovation

Infosys USA certified as Great Place To Work®

Eris Lifesciences Ltd Board declares Interim Dividend of Rs. 5.50

Thomas Cook India Ltd Q1FY21 consolidated loss at Rs. 94.20 crore

PTC India Financial Services Ltd posts consolidated PAT of Rs. 26.56 crore

Sun Pharma Advanced Research Company Ltd Q1FY21 PAT at Rs. 56.69 crore

MRPL Q1 consolidated loss at Rs. 719.78 crore

ITC's Paperboards Unit at Bhadrachalam conferred with GreenCo Platinum+ rating by CII Green Business Centre for its Environmental Stewardship

NMDC registers record jump in production and sales of iron ore in July 2020

Titan Eyeplus in association with Sankara Nethralaya, Chennai launches Teleconsultation Eye care Services for its customers across the country

JSPL Felicitates its COVID-19 warriors

IndiGo repatriated 212 Indians citizens from Russia

Axis Bank Limited announces opening of QIP, floor price fixed as Rs. 442.19

Narayana Hrudalaya Ltd Q1 FY21 Consolidated operating income at Rs 3,935 mn

Tata Consumer Products Ltd announces results for the quarter ended 30th June 2020

Geojit Announces Appointment of Alice G. Vaidyan to the Board

Maruti Suzuki - Delivering sustainable growth through inclusive approach

ASM Technologies Ltd Board recommends interim dividend of Rs. 2

Digitate Launches ignio™ AI.Assurance to Transform Software Testing and Speed Up Software Release Cycles

Lupin Receives Tentative Approval for Empagliflozin Tablets

Sun Pharma launches FluGuard® (Favipiravir) in India at Rs. 35 per tablet

PI Industries Ltd posts consolidated net profit of Rs. 145.5 crore

Tata Consumer Products Ltd Q1FY20 consolidated PAT surges to Rs. 327.56 crore

Zim Laboratories Ltd Q1 consolidated PAT soars to Rs. 3.28 crore

Uniphos Enterprises Ltd posts Rs. 0.25 crore PAT in Q1FY21

Jenburkt Pharmaceuticals Ltd Q1 PAT at Rs. 1 crore

Gujarat Gas Ltd reports Rs. 59.07 crore consolidated PAT in Q1FY21

Unichem Laboratories Ltd Q1FY21 consolidated net profit at Rs. 2.43 crore

Astral Poly Technik Ltd Q1FY21 consolidated PAT falls

Tamilnadu Petroproducts Ltd Q1 consolidated PAT rises QoQ, drops YoY

Geojit Financial Services Ltd Q1FY21 consolidated net profit jumps to Rs. 23.84 crore

Century Enka Ltd posts Rs. 24.90 crore loss in Q1FY21

Vinyl Chemicals India Ltd reports higher net profit of Rs. 1.16 crore in Q1FY21

Bhansali Engineering Polymers Ltd Q1 consolidated loss at Rs. 1.38 crore

Gujarat Sidhee Cement Ltd reports Rs. 4.98 crore consolidated PAT in Q1

Atishay Ltd posts Q1FY21 net profit of Rs. 0.58 crore

Godrej Consumer Products Ltd Q1FY21 consolidated PAT rises QoQ basis

ASM Technologies Ltd Q1FY21 consolidated PAT at Rs. 3.70 crore

Igarashi Motors India Ltd Q1FY21 loss at Rs. 10.52 crore

HIKAL Ltd Q1FY21 consolidated PAT at Rs. 15 crore

Varun Beverages Ltd Board declares Interim Dividend of Rs. 2.50 for CY2020

Deccan Cements Ltd board to announce Q1 results on Aug 14, 2020

Berger Paints India Ltd board to approve quarterly results on Aug 14, 2020

Marksans Pharma Ltd Q1FY21 Revenue at Rs. 331.3 Cr

Ashok Leyland subsidiary Optare delivers first of 21 battery-electric Metrodecker EV with First York

Ashwini Kumar Tewari Takes Charge as The Managing Director and CEO of SBI Card







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019